Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Elena Parovichnikova, Prof MD PhD
- Phone Number: +79161252623
- Email: elenap@blood.ru
Study Contact Backup
- Name: Larisa Kuzmina, MD PhD
- Phone Number: +79161487131
- Email: kuzlara@rambler.ru
Study Locations
-
-
-
Moscow, Russian Federation
- Recruiting
- BMT department
-
Contact:
- Elena Parovichnikova, Prof MD PhD
- Phone Number: +79161487131
- Email: kuzlara@rambler.ru
-
Principal Investigator:
- Elena Parovichnikova
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- allogenic BMT from related or unrelated donor
Exclusion Criteria:
- Severe infection
- Relapse
- admission to ICU
- refusal of research
- patients with graft failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: With MSC
infusion of Mesenchymal stem cells at dose 1 mln cells per kg
|
Mesenchymal stem cells infusion
Other Names:
|
|
No Intervention: Without MSC
Without MSC infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
GVHD
Time Frame: Every 30 day for 1 year after BMT
|
Every 30 day for 1 year after BMT
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall survival
Time Frame: Every 30 day for 1 year after BMT
|
Every 30 day for 1 year after BMT
|
|
Relapse-free survival
Time Frame: Every 30 day for 1 year after BMT
|
Every 30 day for 1 year after BMT
|
|
Infection rate
Time Frame: Every 30 day for 1 year after BMT
|
Every 30 day for 1 year after BMT
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elena Parovichnikova, Prof MD PhD, National Research Center for Hematology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NRCH-MSC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.